☰

Metin Kurtoglu, Ph.D. - Publications

Affiliations: 
2007 University of Miami, Coral Gables, FL 
Area:
Biochemistry, Cell Biology, Oncology
Tree Info Similar researchers PubMed Report error

23 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Liu H, Kurtoglu M, León-Annicchiarico CL, Munoz-Pinedo C, Barredo J, Leclerc G, Merchan J, Liu X, Lampidis TJ. Combining 2-deoxy-D-glucose with fenofibrate leads to tumor cell death mediated by simultaneous induction of energy and ER stress. Oncotarget. PMID 27183907 DOI: 10.18632/Oncotarget.9263  0.719
2015 Kurtoglu M, Davarpanah NN, Qin R, Powles T, Rosenberg JE, Apolo AB. Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer. 13: 410-20. PMID 25862322 DOI: 10.1016/J.Clgc.2015.02.009  0.322
2014 Xi H, Kurtoglu M, Lampidis TJ. The wonders of 2-deoxy-D-glucose. Iubmb Life. 66: 110-21. PMID 24578297 DOI: 10.1002/Iub.1251  0.716
2014 Sullivan EJ, Kurtoglu M, Brenneman R, Liu H, Lampidis TJ. Targeting cisplatin-resistant human tumor cells with metabolic inhibitors. Cancer Chemotherapy and Pharmacology. 73: 417-27. PMID 24352250 DOI: 10.1007/S00280-013-2366-8  0.688
2014 Philips KB, Kurtoglu M, Leung HJ, Liu H, Gao N, Lehrman MA, Murray TG, Lampidis TJ. Increased sensitivity to glucose starvation correlates with downregulation of glycogen phosphorylase isoform PYGB in tumor cell lines resistant to 2-deoxy-D-glucose. Cancer Chemotherapy and Pharmacology. 73: 349-61. PMID 24292700 DOI: 10.1007/S00280-013-2358-8  0.79
2013 Liu H, Kurtoglu M, Cao Y, Xi H, Kumar R, Axten JM, Lampidis TJ. Conversion of 2-deoxyglucose-induced growth inhibition to cell death in normoxic tumor cells. Cancer Chemotherapy and Pharmacology. 72: 251-62. PMID 23700291 DOI: 10.1007/S00280-013-2193-Y  0.756
2013 Raez LE, Papadopoulos K, Ricart AD, Chiorean EG, Dipaola RS, Stein MN, Rocha Lima CM, Schlesselman JJ, Tolba K, Langmuir VK, Kroll S, Jung DT, Kurtoglu M, Rosenblatt J, Lampidis TJ. A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 71: 523-30. PMID 23228990 DOI: 10.1007/S00280-012-2045-1  0.699
2012 Leung HJ, Duran EM, Kurtoglu M, Andreansky S, Lampidis TJ, Mesri EA. Activation of the unfolded protein response by 2-deoxy-D-glucose inhibits Kaposi's sarcoma-associated herpesvirus replication and gene expression. Antimicrobial Agents and Chemotherapy. 56: 5794-803. PMID 22926574 DOI: 10.1128/Aac.01126-12  0.688
2011 Xi H, Kurtoglu M, Liu H, Wangpaichitr M, You M, Liu X, Savaraj N, Lampidis TJ. 2-Deoxy-D-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion. Cancer Chemotherapy and Pharmacology. 67: 899-910. PMID 20593179 DOI: 10.1007/S00280-010-1391-0  0.795
2011 Sullivan EJ, Kurtoglu M, Wangpaichitr M, Savaraj N, Lampidis T. Abstract 4087: Metabolic changes associated with acquired cisplatin resistance Cellular and Molecular Biology. 71: 4087-4087. DOI: 10.1158/1538-7445.Am2011-4087  0.713
2011 Philips KB, Kurtoglu M, Lampidis TJ. Abstract 4064: Overcoming resistance to 2-deoxy-glucose and glucose deprivation in tumor cells under normoxia by modulating the unfolded protein response Cellular and Molecular Biology. 71: 4064-4064. DOI: 10.1158/1538-7445.Am2011-4064  0.787
2011 Leung HJ, Duran M, Kurtoglu M, Lampidis TJ, Mesri EA. Abstract 2725: 2-Deoxyglucose inhibits KSHV replication under normoxic conditions Cancer Research. 71: 2725-2725. DOI: 10.1158/1538-7445.Am2011-2725  0.695
2010 Merchan JR, Kovács K, Railsback JW, Kurtoglu M, Jing Y, Piña Y, Gao N, Murray TG, Lehrman MA, Lampidis TJ. Antiangiogenic activity of 2-deoxy-D-glucose. Plos One. 5: e13699. PMID 21060881 DOI: 10.1371/Journal.Pone.0013699  0.753
2010 Kurtoglu M, Philips K, Liu H, Boise LH, Lampidis TJ. High endoplasmic reticulum activity renders multiple myeloma cells hypersensitive to mitochondrial inhibitors. Cancer Chemotherapy and Pharmacology. 66: 129-40. PMID 19779717 DOI: 10.1007/S00280-009-1143-1  0.736
2010 Xi H, Kurtoglu M, Liu H, Wangpaichitr M, You M, Savaraj N, Lampidis TJ. Abstract 4840: 2-Deoxy-D-glucose induces autophagy through endoplasmic reticulum stress rather than by lowering ATP Cancer Research. 70: 4840-4840. DOI: 10.1158/1538-7445.Am10-4840  0.79
2009 Hohla F, Buchholz S, Schally AV, Seitz S, Rick FG, Szalontay L, Varga JL, Zarandi M, Halmos G, Vidaurre I, Krishan A, Kurtoglu M, Chandna S, Aigner E, Datz C. GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells. Cell Cycle (Georgetown, Tex.). 8: 3149-56. PMID 19755849 DOI: 10.4161/Cc.8.19.9698  0.403
2009 Kurtoglu M, Lampidis TJ. From delocalized lipophilic cations to hypoxia: blocking tumor cell mitochondrial function leads to therapeutic gain with glycolytic inhibitors. Molecular Nutrition & Food Research. 53: 68-75. PMID 19072739 DOI: 10.1002/Mnfr.200700457  0.724
2009 Morales AA, Kurtoglu M, Siefker D, Matulis SM, Gutman DM, Boise LH. Displacement of Bim From Anti-Apoptotic Proteins Is the Primary Factor for Determining ABT-737 Activity in Multiple Myeloma Cell Lines. Blood. 114: 2851-2851. DOI: 10.1182/Blood.V114.22.2851.2851  0.314
2008 Wangpaichitr M, Savaraj N, Maher J, Kurtoglu M, Lampidis TJ. Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-D-glucose under hypoxia in lung cancer cell lines. Molecular Cancer Therapeutics. 7: 1506-13. PMID 18566221 DOI: 10.1158/1535-7163.Mct-07-2334  0.787
2007 Kurtoglu M, Gao N, Shang J, Maher JC, Lehrman MA, Wangpaichitr M, Savaraj N, Lane AN, Lampidis TJ. Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Molecular Cancer Therapeutics. 6: 3049-58. PMID 18025288 DOI: 10.1158/1535-7163.Mct-07-0310  0.806
2007 Kurtoglu M, Maher JC, Lampidis TJ. Differential toxic mechanisms of 2-deoxy-D-glucose versus 2-fluorodeoxy-D-glucose in hypoxic and normoxic tumor cells. Antioxidants & Redox Signaling. 9: 1383-90. PMID 17627467 DOI: 10.1089/Ars.2007.1714  0.828
2007 Maher JC, Wangpaichitr M, Savaraj N, Kurtoglu M, Lampidis TJ. Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose. Molecular Cancer Therapeutics. 6: 732-41. PMID 17308069 DOI: 10.1158/1535-7163.Mct-06-0407  0.793
2006 Lampidis TJ, Kurtoglu M, Maher JC, Liu H, Krishan A, Sheft V, Szymanski S, Fokt I, Rudnicki WR, Ginalski K, Lesyng B, Priebe W. Efficacy of 2-halogen substituted D-glucose analogs in blocking glycolysis and killing "hypoxic tumor cells". Cancer Chemotherapy and Pharmacology. 58: 725-34. PMID 16555088 DOI: 10.1007/S00280-006-0207-8  0.82
Show low-probability matches.